華潤醫藥(03320.HK)中期淨利潤25.77億港元 同比減少15.1%
格隆匯8月27日丨華潤醫藥(03320.HK)公告,截至2020年6月30日止6個月,公司總收益達港幣893.87億元,同比減少12.3%(按照人民幣口徑,報告期間內集團總收益較上年同期減少8.1%)。上半年製藥、醫藥分銷、藥品零售三個主要業務分部的收益佔比分別為14.0%、82.5%以及3.3%。
報告期間內集團實現毛利港幣148.67億元,同比減少14.7%(以人民幣口徑同比減少10.7%);整體毛利率為16.6%,與2019年上半年的毛利率17.1%相比略下降0.5個百分點,主要因為報告期間內毛利率相對高的製藥業務收益降幅超過分銷業務,以及製藥業務的平均毛利率有所下降的綜合原因所致。
期間實現公司擁有人應占溢利港幣25.77億元,同比減少15.1%。如剔除深圳市三九醫院有限公司處置等一次性項目影響,報告期間內集團擁有人應占溢利同比實現增長7.9%。
報告期間內,集團製藥業務實現分部收益港幣139億元,同比下降20.0%,按照人民幣口徑同比下降16.2%,主要因為疫情影響導致集團處方藥業務收入下滑,以及東阿阿膠繼續進行庫存調降、上半年業績同比下滑。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.